Dr. Wang is Vice President and Head of Translational Sciences, Oncology at Arvinas. She has more than 25 years of experience in both industry and academia and an impressive track record of driving impactful contributions in clinical development in oncology and immuno-oncology. Dr. Wang has led research and development teams focusing on translational sciences and precision medicine at pharmaceutical and biotechnology companies for the past 16 years.
Dr. Wang previously served as Senior Director at EMD Serono, a subsidiary of Merck KGaA, where she was Head of Companion Diagnostics (CDx), Clinical Biomarker Expert Team Lead and Department U.S. Site Head, where she oversaw clinical biomarker and CDx strategy and activities from early- to late-stage of clinical development, global regulatory submission and approval, and life cycle management in oncology and immuno-oncology programs.
Prior to this, Dr. Wang was the Head of Protein Diagnostics Development and Technical Lead at Novartis where her team was responsible for end-to-end CDx product development and delivery, as well as overarching clinical biomarker strategy in oncology and immuno-oncology programs.
Dr. Wang received her Ph.D. in Biochemistry from Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing and her M.S.c. and B.S.c. degrees in Cell Biology from Lanzhou University, China. After she completed her postdoctoral fellowship, Dr. Wang was an instructor in the laboratory of Dr. Alan D. D’Andrea at the Dana-Farber Cancer Institute, Harvard Medical School.